Business
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024
BOSTON, March 05, 2024 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and
About this update from Tango Therapeutics, Inc.
[{"type":"text","content":"BOSTON, March 05, 2024 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that one abstract has been selected for an oral minisymposium and seven abstracts have been accepted as poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10, 2024, in San Diego, California. Abstract accepted for oral minisymposium Title: TNG260, a small molecule CoREST inhibitor, sensitizes STK11-mutant NSCLC to anti-PD1 immunotherapyAbstract #: 3916Session Title: Immune Targets and Therapies Presenter: Ayushi Patel, Ph.D., NYU Langone Health Date and Time: Monday April 8, 2024, 2:30 – 4:30 p.m. PT Abstracts accepted for poster presentation Title: Genome-wide drug anchor screens identify CAAP1 and AKAP17A as regulators of PRMT5 inhibitor sensitivityAbstract #: 4636Presenter: Satoshi Yoda, M.D., Ph.D., Principal Scientist, Tango TherapeuticsDate and Time: April 9, 2024, 9:00 a.m. – 12:30 p.m. PT Title: Evaluation of the impact of homozygous MTAP truncations on the activity and selectivity of MTA-cooperative PRMT5 inhibitorsAbstract #: 4631Presenter: Kimberly Briggs, Ph.D., Director, Tango TherapeuticsDate and Time: April 9, 2024, 9:00 a.m. – 12:30 p.m. PT Title: TNG348 is synergistic with PARP inhibitors in tumor models with elevated replication stressAbstract #: 4527Presenter: Antoine Simoneau, Ph.D., Senior Scientist, Tango TherapeuticsDate and Time: April 9, 2024, 9:00 a.m. – 12:30 p.m. PT Title: TNG917 is a clinical-grade, potent and selective inhibitor of EHMT1/2 for the treatment of immune cold tumorsAbstract #: 3242Presenter: Yingnan Chen, Ph.D., Senior Director, Tango TherapeuticsDate and Time: April 8, 2024, 1:30 – 5:00 p.m. PT Title: Experimental ‘loss-of function’ annotation of STK11 mutations with prognostic and therapeutic implicationsAbstract #: 5584Presenters: Silvia Fenoglio, Ph.D., Principal Scientist, Tango Therapeutics and Brian Haines, Ph.D., Vice President, Tango Therapeutics Date and Time: April 9, 2024, 1:30 – 5:00 p.m. PT Title: LIG1 inactivation selectively inhibits growth of BRCA1 mutant cells in vitro and in vivoAbstract #: 3363Presenter: Hilary Nicholson, Ph.D., Principal Scientist, Tango TherapeuticsDate and ...